Abstract: Systemic treatment of advanced hepatocellular carcinoma (HCC) includes targeted therapy, chemotherapy, and immunotherapy. In recent years, the treatment of advanced HCC has progressed with the use of programmed death receptor-1(PD-1)/programmed death receptor-1 ligand (PD-L1) inhibitors. Nivolumab and pembrolizumab have been approved by the US Food and Drug Administration (FDA) as a second-line treatment for advanced HCC. Multiple phase I/II clinical studies of PD-1/PD-L1 inhibitors combined with other systemic treatments have revealed good efficacy and safety. In a phase III clinical study, atezolizumab plus bevacizumab, as a new first-line treatment strategy, has been shown to be superior to the existing standard treatment (sorafenib). Here, we review the current research and progress in the use of PD-1/PD-L1 inhibitors for advanced HCC.